AtheroGenics Strengthens Management Team to Accelerate Product Development
Promotes Mitchell Glass, M.D. to Senior Vice President of Strategic Drug Development; Judith R. Jaeger, M.D. Joins the Company as Vice President Of Clinical Development and Regulatory Affairs
ATLANTA, Jan. 9 /PRNewswire/ -- AtheroGenics, Inc. (Nasdaq: AGIX - news), an Atlanta-based emerging pharmaceutical company, announced today senior management changes designed to enhance its drug development capabilities. Mitchell Glass, M.D. has been promoted to Senior Vice President - Strategic Drug Development and will serve as chairman of the company's pharmaceutical review board. Additionally, Judith R. Jaeger, M.D., a senior research and development executive and immunology specialist, has joined the company as Vice President of Clinical Development and Regulatory Affairs. Both executives will report to Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer.
Dr. Glass joined AtheroGenics as Vice President, Clinical Development and Regulatory Affairs in 1997, managing the company's clinical programs. Since that time, Dr. Glass has directed the progression of the company's lead compound, AGI-1067, through early stage clinical trials and into a robust Phase II trial studying the compound in post-angioplasty restenosis. Dr. Glass has built a dynamic and growing drug development team and has directed several pre-clinical drug development programs studying other anti- inflammatory compounds in a variety of therapeutic areas. As Senior Vice President - Strategic Drug Development, Dr. Glass will assist in the design and articulation of the strategic plans for the company's drug development programs and clinical market opportunities. As chairman of the company's pharmaceutical review board, Dr. Glass will help ensure the progress and growth in value of the company's drug development programs and take on the role of strategic advisor to the president and CEO in areas of drug development.
Dr. Jaeger joins AtheroGenics as Vice President of Clinical Development and Regulatory Affairs. Dr. Jaeger's industry experience began in 1983 at Boehringer Ingelheim Pharmaceuticals, Inc., where she served in a number of management positions in drug development. At Boehringer Ingelheim, Dr. Jaeger directed programs in inflammation, immunology and pulmonary disorders, with a recent focus on cell adhesion molecules. She also represented clinical research in a variety of business development activities at the company. Dr. Jaeger will be a member of AtheroGenics' executive management team. Her responsibilities will include the overall design and management of the clinical trials programs for the company, the development of the company's therapeutic products, and the management and administration of the company's clinical development and regulatory affairs department.
Russell M. Medford, M.D., Ph.D., said, ``Today's management announcements reflect the vitality of the company's commitment to expanding both AtheroGenics' internal drug development capabilities and its ability to identify and evaluate complementary external clinical stage compounds. Drs. Glass and Jaeger have proven track records in the industry, and in guiding our compound candidates through clinical trials will be major contributors to enhancing shareholder value at AtheroGenics.''
AtheroGenics, Inc., through its proprietary vascular protectant drug discovery technology platform, is focused on the discovery, development and commercialization of novel therapeutics for the treatment of chronic inflammatory diseases such as heart disease atherosclerosis), asthma and arthritis. The company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels of the heart. AGI-1067 has recently completed dosing in a 300- patient Phase II clinical study for post-angioplasty restenosis.<snip> |
